Base de dados : MEDLINE
Pesquisa : D09.408.348.800 [Categoria DeCS]
Referências encontradas : 995 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 100 ir para página                         

  1 / 995 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28420651
[Au] Autor:Russo P; Tomé AL; Capela T; Bettencourt MJ
[Ad] Endereço:Department of Gastroenterology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
[Ti] Título:Anorectal involvement in a patient with multiple myeloma.
[So] Source:BMJ Case Rep;2017, 2017 Apr 18.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Multiple myeloma is a neoplastic proliferation of monoclonal plasma cells. Symptomatic gastrointestinal involvement is uncommon. We report the case of a 45-year-old patient admitted with an anorectal polypoid lesion, which progressed to colonic obstruction. Investigation revealed a secondary plasmacytoma associated with multiple myeloma. We discuss the characteristics of this rare entity with poor prognosis, its clinical implications and treatment options.
[Mh] Termos MeSH primário: Mieloma Múltiplo/cirurgia
Plasmocitoma/secundário
Neoplasias Retroperitoneais/diagnóstico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ciclofosfamida/administração & dosagem
Ciclofosfamida/uso terapêutico
Dexametasona/administração & dosagem
Dexametasona/uso terapêutico
Evolução Fatal
Seres Humanos
Masculino
Meia-Idade
Prognóstico
Neoplasias Retroperitoneais/tratamento farmacológico
Neoplasias Retroperitoneais/cirurgia
Sigmoidoscopia
Teniposídeo/administração & dosagem
Teniposídeo/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
7S5I7G3JQL (Dexamethasone); 8N3DW7272P (Cyclophosphamide); 957E6438QA (Teniposide)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE


  2 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28033329
[Au] Autor:Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
[Ad] Endereço:Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
[Ti] Título:Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
[So] Source:PLoS One;11(12):e0168113, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microenvironment, we investigated whether the MI concentration in the tumor changes during therapy. METHODS: We used 1H-magnetic resonance spectroscopy to measure the MI concentrations in the tumor and contralateral control tissue of 39 prospectively recruited patients with recurrent glioblastomas before and 8-12 weeks after starting therapy. 30 patients received Bevacizumab and 9 patients were treated with CCNU/VM26 as control. We performed a survival analysis to evaluate MI as a predictive biomarker for Bevacizumab therapy. RESULTS: MI concentrations increased significantly during Bevacizumab therapy in tumor (p < .001) and control tissue (p = .001), but not during CCNU/VM26 treatment. For the Bevacizumab cohort, higher MI concentrations in the control tissue at baseline (p = .021) and higher differences between control and tumor tissue (delta MI, p = .011) were associated with longer survival. A Kaplan-Meier analysis showed a median OS of 164 days for patients with a deltaMI < 1,817 mmol/l and 275 days for patients with a deltaMI > 1,817 mmol/l. No differences were observed for the relative changes or the post treatment concentrations. Additionally calculated creatine concentrations showed no differences in between subgroups or between pre and post treatment measurements. CONCLUSION: Our data suggest that recurrent glioblastoma shows a strong metabolic reaction to Bevacizumab. Further, our results support the hypothesis that MI might be a marker for early tumor cell invasion. Pre-therapeutic MI concentrations are predictive of overall survival in patients with recurrent glioblastoma treated with Bevacizumab.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Bevacizumab/uso terapêutico
Biomarcadores Tumorais/metabolismo
Glioblastoma/tratamento farmacológico
Inositol/metabolismo
Espectroscopia de Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/uso terapêutico
Neoplasias Encefálicas/tratamento farmacológico
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/patologia
Feminino
Glioblastoma/mortalidade
Glioblastoma/patologia
Seres Humanos
Hidrogênio/química
Lomustina/uso terapêutico
Imagem por Ressonância Magnética/métodos
Masculino
Meia-Idade
Estudos Prospectivos
Análise de Sobrevida
Teniposídeo/uso terapêutico
Microambiente Tumoral/efeitos dos fármacos
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
Fator A de Crescimento do Endotélio Vascular/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 2S9ZZM9Q9V (Bevacizumab); 4L6452S749 (Inositol); 7BRF0Z81KG (Lomustine); 7YNJ3PO35Z (Hydrogen); 957E6438QA (Teniposide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170706
[Lr] Data última revisão:
170706
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161230
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168113


  3 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27622579
[Au] Autor:Ivanov DP; Al-Rubai AJ; Grabowska AM; Pratten MK
[Ad] Endereço:Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, UK. Electronic address: delyan.ivanov@nottingham.ac.uk.
[Ti] Título:Separating chemotherapy-related developmental neurotoxicity from cytotoxicity in monolayer and neurosphere cultures of human fetal brain cells.
[So] Source:Toxicol In Vitro;37:88-96, 2016 Dec.
[Is] ISSN:1879-3177
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chemotherapy-induced neurotoxicity can reduce the quality of life of patients by affecting their intelligence, senses and mobility. Ten percent of safety-related late-stage clinical failures are due to neurological side effects. Animal models are poor in predicting human neurotoxicity due to interspecies differences and most in vitro assays cannot distinguish neurotoxicity from general cytotoxicity for chemotherapeutics. We developed in vitro assays capable of quantifying the paediatric neurotoxic potential for cytotoxic drugs. Mixed cultures of human fetal brain cells were differentiated in monolayers and as 3D-neurospheres in the presence of non-neurotoxic chemotherapeutics (etoposide, teniposide) or neurotoxicants (methylmercury). The cytotoxic potency towards dividing progenitors versus differentiated neurons and astrocytes was compared using: (1) immunohistochemistry staining and cell counts in monolayers; (2) through quantitative Western blots in neurospheres; and (3) neurosphere migration assays. Etoposide and teniposide, were 5-10 times less toxic to differentiated neurons compared to the mix of all cells in monolayer cultures. In contrast, the neurotoxicant methylmercury did not exhibit selectivity and killed all cells with the same potency. In 3D neurospheres, etoposide and teniposide were 24 to 10 times less active against neurons compared to all cells. These assays can be used prioritise drugs for local drug delivery to brain tumours.
[Mh] Termos MeSH primário: Antineoplásicos/toxicidade
Astrócitos/efeitos dos fármacos
Etoposídeo/toxicidade
Compostos de Metilmercúrio/toxicidade
Neurônios/efeitos dos fármacos
Teniposídeo/toxicidade
[Mh] Termos MeSH secundário: Astrócitos/metabolismo
Encéfalo/citologia
Contagem de Células
Técnicas de Cultura de Células
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Feto
Proteína Glial Fibrilar Ácida/metabolismo
Seres Humanos
Neurônios/metabolismo
Síndromes Neurotóxicas
Oxazinas/metabolismo
Oxirredução
Esferoides Celulares/efeitos dos fármacos
Esferoides Celulares/metabolismo
Tubulina (Proteína)/metabolismo
Xantenos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Glial Fibrillary Acidic Protein); 0 (Methylmercury Compounds); 0 (Oxazines); 0 (TUBB3 protein, human); 0 (Tubulin); 0 (Xanthenes); 1FN9YD6968 (resazurin); 6PLQ3CP4P3 (Etoposide); 957E6438QA (Teniposide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160914
[St] Status:MEDLINE


  4 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27596115
[Au] Autor:Chu B; Shi S; Li X; Hu L; Shi L; Zhang H; Xu Q; Ye L; Lin G; Zhang N; Zhang X
[Ad] Endereço:Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou 325000, PR China. Electronic address: chubingyang@126.com.
[Ti] Título:Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy.
[So] Source:Int J Pharm;513(1-2):118-129, 2016 Nov 20.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Self-assembled polymeric micelles have been widely applied in anticancer drug delivery systems. Teniposide is a broad spectrum and effective anticancer drug, but its poor water-solubility and adverse effects of commercial formulation (VM-26) restrict its clinical application. In this work, teniposide-loaded polymeric micelles were prepared based on monomethoxy-poly(ethylene glycol)-poly(ε-caprolactone-co-d,l- lactide) (MPEG-PCLA) copolymers through a thin-film hydration method to improve the hydrophilic and reduce the systemic toxicity. The prepared teniposide micelles were without any surfactants or additives and monodisperse with a mean particle size of 29.6±0.3nm. The drug loading and encapsulation efficiency were 18.53±0.41% and 92.63±2.05%, respectively. The encapsulation of teniposide in MPEG-PCLA micelles showed a slow and sustained release behavior of teniposide in vitro and improved the terminal half-life (t ), the area under the plasma concentration-time curve (AUC) and retention time of teniposide in vivo compared with VM-26. In addition, teniposide micelles also enhanced the cellular uptake by MCF-7 breast cancer cells in vitro and increased the distribution in tumors in vivo. Teniposide micelles showed an excellent safety with a maximum tolerated dose (MTD) of approximately 50mg teniposide/kg body weight, which was 2.5-fold higher than that of VM-26 (about 20mg teniposide/kg body weight). Furthermore, the intravenous application of teniposide micelles effectively suppressed the growth of subcutaneous MCF-7 tumor in vivo and exhibited a stronger anticancer effect than that of VM-26. These results suggested that we have successfully prepared teniposide-loaded MPEG-PCLA micelles with improved safety, hydrophilic and therapeutic efficiency, which are efficient for teniposide delivery. The prepared teniposide micelles may be promising in breast cancer therapy.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Neoplasias da Mama/tratamento farmacológico
Portadores de Fármacos/química
Teniposídeo/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacocinética
Antineoplásicos/farmacologia
Área Sob a Curva
Neoplasias da Mama/patologia
Preparações de Ação Retardada
Sistemas de Liberação de Medicamentos
Feminino
Meia-Vida
Seres Humanos
Interações Hidrofóbicas e Hidrofílicas
Células MCF-7
Dose Máxima Tolerável
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Nus
Micelas
Tamanho da Partícula
Poliésteres/química
Polietilenoglicóis/química
Ratos
Ratos Sprague-Dawley
Solubilidade
Teniposídeo/farmacocinética
Teniposídeo/farmacologia
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Delayed-Action Preparations); 0 (Drug Carriers); 0 (Micelles); 0 (Polyesters); 0 (poly(epsilon-caprolactone-co-lactide)); 30IQX730WE (Polyethylene Glycols); 9004-74-4 (monomethoxypolyethylene glycol); 957E6438QA (Teniposide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160907
[St] Status:MEDLINE


  5 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26916150
[Au] Autor:Liu H; Liao JX; Hu Y; Tu YH; Sun JS
[Ad] Endereço:The National Engineering Research Centre for Carbohydrate Synthesis, Jiangxi Normal University , Nanchang 330022, China.
[Ti] Título:A Highly Efficient Approach To Construct (epi)-Podophyllotoxin-4-O-glycosidic Linkages as well as Its Application in Concise Syntheses of Etoposide and Teniposide.
[So] Source:Org Lett;18(6):1294-7, 2016 Mar 18.
[Is] ISSN:1523-7052
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:By taking full advantage of the mild promotion conditions of an ortho-alkynylbenzoate glycosylation protocol, a highly efficient approach to construct the challenging (epi)-podophyllotoxin 4-O-glycosidic linkages was devised under the activation of a catalytic amount of a Au(I) complex. The novel method enjoys a quite broad substrate scope in terms of both glycosyl donors and podophyllotoxin derivative acceptors, providing the desired glycosides in excellent yields. Based on the new approach, concise syntheses of clinically used anticancer reagents etoposide and teniposide were accomplished, and the overall yields counting from easily available starting materials could reach as high as 18% and 9%, respectively.
[Mh] Termos MeSH primário: Antineoplásicos/síntese química
Etoposídeo/síntese química
Podofilotoxina/química
Teniposídeo/síntese química
[Mh] Termos MeSH secundário: Antineoplásicos/química
Catálise
Etoposídeo/química
Glicosídeos/síntese química
Glicosídeos/química
Glicosilação
Estrutura Molecular
Teniposídeo/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Glycosides); 6PLQ3CP4P3 (Etoposide); 957E6438QA (Teniposide); L36H50F353 (Podophyllotoxin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160318
[Lr] Data última revisão:
160318
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160227
[St] Status:MEDLINE
[do] DOI:10.1021/acs.orglett.6b00216


  6 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26583611
[Au] Autor:Nascimento FA; Nery J; Trennepohl J; Pianovski MA
[Ad] Endereço:*Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada †Department of Pediatrics, Pequeno Príncipe Hospital ‡Department of Pediatrics, Hospital de Clínicas, Federal University of Paraná, Curitiba, Paraná, Brazil.
[Ti] Título:Hemophagocytic Lymphohistiocytosis After Initiation of Chemotherapy for Bilateral Adrenal Neuroblastoma.
[So] Source:J Pediatr Hematol Oncol;38(1):e13-5, 2016 Jan.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hemophagocytic lymphohistiocytosis (HLH) is a rare and aggressive syndrome characterized by overactivation of the immune system. Although secondary HLH has been frequently associated with malignancies, this entity is rarely triggered by solid tumors, such as neuroblastomas. Herein, we describe a 14-month-old girl with a late diagnosis of bilateral adrenal neuroblastoma who developed HLH 6 days after the initiation of chemotherapy. On the basis of the large tumoral mass and the time of onset of her symptoms suggestive of HLH, we hypothesize that tumor cell destruction induced by chemotherapy drugs was the trigger to the development of hematophagocytic lymphohistiocytosis syndrome.
[Mh] Termos MeSH primário: Neoplasias das Glândulas Suprarrenais/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Linfo-Histiocitose Hemofagocítica/induzido quimicamente
Neuroblastoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Doxorrubicina/administração & dosagem
Doxorrubicina/efeitos adversos
Feminino
Seres Humanos
Lactente
Teniposídeo/administração & dosagem
Teniposídeo/efeitos adversos
Vincristina/administração & dosagem
Vincristina/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
5J49Q6B70F (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 957E6438QA (Teniposide)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:151216
[Lr] Data última revisão:
151216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151120
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000000469


  7 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26763064
[Au] Autor:Singapore Cancer Network (SCAN) Neuro-Oncology Workgroup
[Ti] Título:Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
[So] Source:Ann Acad Med Singapore;44(10):463-73, 2015 Oct.
[Is] ISSN:0304-4602
[Cp] País de publicação:Singapore
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The SCAN Neuro-Oncology workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for high-grade glioma in Singapore. MATERIALS AND METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS: Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2013), the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma (2014), the European Society of Medical Oncology (2014), the Canadian GBM Recommendations Committee (2007) and the Australian Cancer Network (2009). Recommendations on the systemic therapy of high-grade glioma were produced. CONCLUSION: These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of high-grade glioma.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Astrocitoma/terapia
Neoplasias Encefálicas/terapia
Glioblastoma/terapia
Recidiva Local de Neoplasia/terapia
Oligodendroglioma/terapia
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/administração & dosagem
Astrocitoma/genética
Astrocitoma/patologia
Bevacizumab/administração & dosagem
Neoplasias Encefálicas/patologia
Camptotecina/administração & dosagem
Camptotecina/análogos & derivados
Carboplatina/administração & dosagem
Quimiorradioterapia
Quimioterapia Adjuvante
Cromossomos Humanos Par 1/genética
Cromossomos Humanos Par 19/genética
Ciclofosfamida/administração & dosagem
Dacarbazina/administração & dosagem
Dacarbazina/análogos & derivados
Glioblastoma/patologia
Seres Humanos
Lomustina
Gradação de Tumores
Recidiva Local de Neoplasia/patologia
Oligodendroglioma/genética
Oligodendroglioma/patologia
Procarbazina
Radioterapia
Singapura
Teniposídeo/administração & dosagem
Vincristina
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 2S9ZZM9Q9V (Bevacizumab); 35S93Y190K (Procarbazine); 5J49Q6B70F (Vincristine); 6NS400BXKH (nimotuzumab); 7673326042 (irinotecan); 7BRF0Z81KG (Lomustine); 7GR28W0FJI (Dacarbazine); 8N3DW7272P (Cyclophosphamide); 957E6438QA (Teniposide); BG3F62OND5 (Carboplatin); XT3Z54Z28A (Camptothecin); YF1K15M17Y (temozolomide)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160115
[St] Status:MEDLINE


  8 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26253377
[Au] Autor:He S; Cui Z; Wang X; Zhang H; Dai W; Zhang Q
[Ad] Endereço:State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China; Medical College, Henan University of Science & Technology, Luoyang 471003, People's Republic of China.
[Ti] Título:Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo.
[So] Source:Int J Pharm;495(1):144-53, 2015 Nov 10.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The study was designed to identify the safety and antitumor activity of teniposide self-microemulsified drug delivery system (TEN-SMEDDS) previously developed, and to provide evidence for the feasibility and effectiveness of TEN-SMEDDS for application in clinic. The TEN-SMEDDS could form fine emulsion with mean diameter of 279 ± 19 nm, Zeta potential of -6.9 ± 1.4 mV, drug loading of 0.04 ± 0.001% and entrapment efficiency of 98.7 ± 1.6% after dilution with 5% glucose, respectively. The safety, including hemolysis, hypersensitivity, vein irritation and toxicity in vivo, and antitumor activity were assessed, VUNON as a reference. Sulforhodamine B assays demonstrated that the IC50 of TEN-SMEDDS against C6 and U87MG cells were higher than that of VUMON. But the effect of TEN-SMEDDS on the cell cycle distribution and cell apoptotic rate was similar to that of VUMON as observed by flow cytometry. Likewise, the antitumor activity of TEN-SMEDDS was considerable to that of VUMON. Finally, the TEN-SMEDDS exhibited less body weight loss, lower hemolysis and lower myelosuppression as compared with VUMON. In conclusion, promising TEN-SMEDDS retained the antitumor activity of teniposide and was less likely to cause some side effects compared to VUMON. It may be favorable for the application in clinic.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos
Emulsões/efeitos adversos
Emulsões/farmacologia
Polietilenoglicóis
Teniposídeo/efeitos adversos
Teniposídeo/farmacologia
[Mh] Termos MeSH secundário: Administração Intravenosa
Animais
Apoptose/efeitos dos fármacos
Ciclo Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Hipersensibilidade a Drogas
Ensaios de Seleção de Medicamentos Antitumorais
Emulsões/administração & dosagem
Feminino
Cobaias
Hemólise/efeitos dos fármacos
Seres Humanos
Masculino
Camundongos
Polietilenoglicóis/análise
Coelhos
Testes de Irritação da Pele
Teniposídeo/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emulsions); 30IQX730WE (Polyethylene Glycols); 39279-69-1 (cremophor); 957E6438QA (Teniposide)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150809
[St] Status:MEDLINE


  9 / 995 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25914138
[Au] Autor:Liu M; Chen Y; Zhang L; Wang Q; Ma X; Li X; Xiang R; Zhu Y; Qin S; Yu Y; Jiang XC; Duan Y; Han J
[Ad] Endereço:From the State Key Laboratory of Medicinal Chemical Biology, Colleges of Life Sciences and.
[Ti] Título:Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.
[So] Source:J Biol Chem;290(23):14418-29, 2015 Jun 05.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from high density lipoprotein to triglyceride-rich lipoproteins. CETP expression can be transcriptionally activated by liver X receptor (LXR). Etoposide and teniposide are DNA topoisomerase II (Topo II) inhibitors. Etoposide has been reported to inhibit atherosclerosis in rabbits with un-fully elucidated mechanisms. In this study we determined if Topo II activity can influence cholesterol metabolism by regulating hepatic CETP expression. Inhibition of Topo II by etoposide, teniposide, or Topo II siRNA increased CETP expression in human hepatic cell line, HepG2 cells, which was associated with increased CETP secretion and mRNA expression. Meanwhile, inhibition of LXR expression by LXR siRNA attenuated induction of CETP expression by etoposide and teniposide. Etoposide and teniposide induced LXRα expression and LXRα/ß nuclear translocation while inhibiting expression of receptor interacting protein 140 (RIP140), an LXR co-repressor. In vivo, administration of teniposide moderately reduced serum lipid profiles, induced CETP expression in the liver, and activated reverse cholesterol transport in CETP transgenic mice. Our study demonstrates a novel function of Topo II inhibitors in cholesterol metabolism by activating hepatic CETP expression and reverse cholesterol transport.
[Mh] Termos MeSH primário: Proteínas de Transferência de Ésteres de Colesterol/genética
Colesterol/metabolismo
DNA Topoisomerases Tipo II/metabolismo
Etoposídeo/farmacologia
Regulação da Expressão Gênica/efeitos dos fármacos
Teniposídeo/farmacologia
Inibidores da Topoisomerase II/farmacologia
[Mh] Termos MeSH secundário: Animais
Proteínas de Transferência de Ésteres de Colesterol/metabolismo
Células Hep G2
Seres Humanos
Fígado/efeitos dos fármacos
Fígado/metabolismo
Receptores X do Fígado
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Receptores Nucleares Órfãos/genética
Receptores Nucleares Órfãos/metabolismo
Transporte Proteico/efeitos dos fármacos
Ativação Transcricional/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cholesterol Ester Transfer Proteins); 0 (Liver X Receptors); 0 (NR1H3 protein, human); 0 (Nr1h3 protein, mouse); 0 (Orphan Nuclear Receptors); 0 (Topoisomerase II Inhibitors); 6PLQ3CP4P3 (Etoposide); 957E6438QA (Teniposide); 97C5T2UQ7J (Cholesterol); EC 5.99.1.3 (DNA Topoisomerases, Type II)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150428
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M115.643015


  10 / 995 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25899285
[Au] Autor:He X; Xiang N; Zhang J; Zhou J; Fu Y; Gong T; Zhang Z
[Ad] Endereço:Key Laboratory of Drug Targeting, Ministry of Education, Sichuan University, No. 17. Section 3. Southern Renmin Road, Chengdu 610041, People's Republic of China.
[Ti] Título:Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity.
[So] Source:Int J Pharm;487(1-2):250-9, 2015 Jun 20.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Teniposide (VM-26) is a semisynthetic derivative of podophyllotoxin effective for the treatment of many types of tumors. However, the poor water solubility and adverse effects restrict its clinical use. Our study aimed to develop a novel phospholipid complex albumin nanoparticle (VM-E80-AN) to reduce the systemic toxicity and enhance antitumor activity of VM-26. Egg yolk lecithin E80 and human serum albumin (HSA) were used as the main excipients to replace Cremophor EL in the commercial formulation. The physicochemical properties of VM-E80-AN were characterized to optimize the formulation. Cell and animal studies were further carried out to estimate its tumor inhibition efficacy, biodistribution, and toxicity. Comparison between VM-26 solution and VM-E80-AN showed that VM-E80-AN significantly reduced the toxicity of VM-26 and enhanced the anticancer efficacy of the drug. Thus, VM-E80-AN represents a safe and promising formulation of teniposide for clinical application.
[Mh] Termos MeSH primário: Antineoplásicos Fitogênicos/administração & dosagem
Antineoplásicos Fitogênicos/farmacologia
Teniposídeo/administração & dosagem
Teniposídeo/farmacologia
[Mh] Termos MeSH secundário: Albuminas
Animais
Antineoplásicos Fitogênicos/efeitos adversos
Linhagem Celular
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Química Farmacêutica
Excipientes
Seres Humanos
Lecitinas
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Nanopartículas
Ratos
Ratos Wistar
Teniposídeo/efeitos adversos
Distribuição Tecidual
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Albumins); 0 (Antineoplastic Agents, Phytogenic); 0 (Excipients); 0 (Lecithins); 957E6438QA (Teniposide)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150513
[Lr] Data última revisão:
150513
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150423
[St] Status:MEDLINE



página 1 de 100 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde